{"id":"https://openalex.org/W2912376565","doi":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","title":"Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).","display_name":"Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).","publication_year":2019,"publication_date":"2019-01-29","ids":{"openalex":"https://openalex.org/W2912376565","doi":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","mag":"2912376565"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2019.37.4_suppl.tps725","doi":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2912376565"],"child_works_count":0,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5001020016","display_name":"Joel Randolph Hecht","orcid":"https://orcid.org/0000-0003-2277-4157","observed_orcids":["https://orcid.org/0000-0003-2277-4157"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"J. Randolph Hecht","raw_affiliation_strings":["David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005769474","display_name":"Arlene Chan","orcid":"https://orcid.org/0000-0003-2135-2286","observed_orcids":["https://orcid.org/0000-0003-2135-2286"]},"institutions":[{"id":"https://openalex.org/I205640436","display_name":"Curtin University","ror":"https://ror.org/02n415q13","country_code":"AU","type":"education","lineage":["https://openalex.org/I205640436"]}],"countries":["AU"],"is_corresponding":false,"raw_author_name":"Arlene Chan","raw_affiliation_strings":["Breast Cancer Research Centre - WA & Curtin University, Perth, Australia;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Breast Cancer Research Centre - WA & Curtin University, Perth, Australia;","institution_ids":["https://openalex.org/I205640436"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100671433","display_name":"Miguel Mart\u00edn","orcid":"https://orcid.org/0000-0001-9237-3231","observed_orcids":["https://orcid.org/0000-0001-9237-3231"]},"institutions":[{"id":"https://openalex.org/I2960094004","display_name":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n","ror":"https://ror.org/0111es613","country_code":"ES","type":"healthcare","lineage":["https://openalex.org/I2960094004","https://openalex.org/I4210139293"]}],"countries":["ES"],"is_corresponding":false,"raw_author_name":"Miguel Martin","raw_affiliation_strings":["Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Hospital General Universitario Gregorio Mara\u00f1\u00f3n, Madrid, Spain;","institution_ids":["https://openalex.org/I2960094004"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020235177","display_name":"Nicolas Mach","orcid":"https://orcid.org/0000-0001-8944-1088","observed_orcids":["https://orcid.org/0000-0001-8944-1088"]},"institutions":[{"id":"https://openalex.org/I4210106256","display_name":"University Hospital of Geneva","ror":"https://ror.org/01m1pv723","country_code":"CH","type":"healthcare","lineage":["https://openalex.org/I4210106256"]},{"id":"https://openalex.org/I4405269708","display_name":"Fondation Dr Henri Dubois-Ferri\u00e8re Dinu Lipatti","ror":"https://ror.org/04zmzd388","country_code":"CH","type":"nonprofit","lineage":["https://openalex.org/I4405269708"]}],"countries":["CH"],"is_corresponding":false,"raw_author_name":"Nicolas Mach","raw_affiliation_strings":["Clinical Research Unit of the Foundation Dr. Henri Dubois-Ferri\u00e8re Dinu Lipatti, Oncology Center, HUG, Gen\u00e8ve, Switzerland, Gen\u00e8ve, Switzerland;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Clinical Research Unit of the Foundation Dr. Henri Dubois-Ferri\u00e8re Dinu Lipatti, Oncology Center, HUG, Gen\u00e8ve, Switzerland, Gen\u00e8ve, Switzerland;","institution_ids":["https://openalex.org/I4210106256","https://openalex.org/I4405269708"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068059897","display_name":"Sara Alsterlind Hurvitz","orcid":"https://orcid.org/0000-0001-7808-7191","observed_orcids":["https://orcid.org/0000-0001-7808-7191"]},"institutions":[{"id":"https://openalex.org/I161318765","display_name":"University of California, Los Angeles","ror":"https://ror.org/046rm7j60","country_code":"US","type":"education","lineage":["https://openalex.org/I161318765"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sara A. Hurvitz","raw_affiliation_strings":["UCLA David Geffen School of Medicine, Los Angeles, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCLA David Geffen School of Medicine, Los Angeles, CA;","institution_ids":["https://openalex.org/I161318765"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043348199","display_name":"Sylvie Rottey","orcid":"https://orcid.org/0000-0003-2060-3725","observed_orcids":["https://orcid.org/0000-0003-2060-3725"]},"institutions":[{"id":"https://openalex.org/I2801227569","display_name":"Ghent University Hospital","ror":"https://ror.org/00xmkp704","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2801227569"]}],"countries":["BE"],"is_corresponding":false,"raw_author_name":"Sylvie Rottey","raw_affiliation_strings":["Ghent University Hospital, Heymans Institute of Pharmacology, Ghent, Belgium;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Ghent University Hospital, Heymans Institute of Pharmacology, Ghent, Belgium;","institution_ids":["https://openalex.org/I2801227569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006886614","display_name":"Uwe Pelzer","orcid":"https://orcid.org/0000-0001-9213-2737","observed_orcids":["https://orcid.org/0000-0001-9213-2737"]},"institutions":[{"id":"https://openalex.org/I7877124","display_name":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin","ror":"https://ror.org/001w7jn25","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I7877124"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Uwe Pelzer","raw_affiliation_strings":["Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, BS, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Charit\u00e9 \u2013 Universit\u00e4tsmedizin Berlin, Berlin, BS, Germany;","institution_ids":["https://openalex.org/I7877124"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075449558","display_name":"Chunxu Liu","orcid":"https://orcid.org/0009-0005-5179-4116","observed_orcids":["https://orcid.org/0009-0005-5179-4116","https://orcid.org/0000-0002-2802-0797"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chunxu Liu","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5112732499","display_name":"Emily Chan","orcid":"https://orcid.org/0009-0008-7042-7217","observed_orcids":["https://orcid.org/0009-0008-7042-7217"]},"institutions":[{"id":"https://openalex.org/I1320553840","display_name":"Amgen (United States)","ror":"https://ror.org/03g03ge92","country_code":"US","type":"company","lineage":["https://openalex.org/I1320553840"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Emily Chan","raw_affiliation_strings":["Amgen Inc., Thousand Oaks, CA;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amgen Inc., Thousand Oaks, CA;","institution_ids":["https://openalex.org/I1320553840"]}]}],"institutions":[],"countries_distinct_count":6,"institutions_distinct_count":8,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"37","issue":"4_suppl","first_page":"TPS725","last_page":"TPS725"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.6122999787330627,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.6122999787330627,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.29829999804496765,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.01489999983459711,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/talimogene-laherparepvec","display_name":"talimogene laherparepvec","score":0.9980000257492065},{"id":"https://openalex.org/keywords/oncolytic-herpes-simplex-virus-type-1","display_name":"oncolytic herpes simplex virus type 1","score":0.9290000200271606},{"id":"https://openalex.org/keywords/atezolizumab","display_name":"atezolizumab","score":0.9369999766349792},{"id":"https://openalex.org/keywords/liver-metastases","display_name":"liver metastasis","score":0.796999990940094},{"id":"https://openalex.org/keywords/metastatic-triple-negative-breast-cancer","display_name":"metastatic triple-negative breast cancer","score":0.9509999752044678},{"id":"https://openalex.org/keywords/metastatic-colorectal-cancer","display_name":"metastatic colorectal cancer","score":0.9480000138282776},{"id":"https://openalex.org/keywords/intralesional-injection","display_name":"intralesional injection","score":0.7170000076293945},{"id":"https://openalex.org/keywords/pd-l1-inhibitors","display_name":"PD-L1 inhibitors","score":0.8149999976158142},{"id":"https://openalex.org/keywords/combination-immunotherapy","display_name":"combination immunotherapy","score":0.6600000262260437},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9210000038146973},{"id":"https://openalex.org/keywords/safety","display_name":"safety","score":0.382999986410141},{"id":"https://openalex.org/keywords/gm-csf","display_name":"GM-CSF","score":0.5789999961853027},{"id":"https://openalex.org/keywords/cancer-immunotherapy","display_name":"cancer immunotherapy","score":0.4429999887943268},{"id":"https://openalex.org/keywords/objective-response-rate","display_name":"objective response rate","score":0.5419999957084656},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.9240000247955322}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9206910133361816},{"id":"https://openalex.org/C2775949291","wikidata":"https://www.wikidata.org/wiki/Q20707748","display_name":"Atezolizumab","level":5,"score":0.8364143371582031},{"id":"https://openalex.org/C82210918","wikidata":"https://www.wikidata.org/wiki/Q1560099","display_name":"Oncolytic virus","level":3,"score":0.6318753957748413},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.6221957206726074},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6005532741546631},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5202063918113708},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.47693270444869995},{"id":"https://openalex.org/C526805850","wikidata":"https://www.wikidata.org/wiki/Q188874","display_name":"Colorectal cancer","level":3,"score":0.43859991431236267},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4117392599582672},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.35528630018234253},{"id":"https://openalex.org/C2780057760","wikidata":"https://www.wikidata.org/wiki/Q13896859","display_name":"Pembrolizumab","level":4,"score":0.3024429678916931}],"mesh":[],"locations_count":2,"locations":[{"id":"doi:10.1200/jco.2019.37.4_suppl.tps725","doi":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2019.37.4_suppl.tps725","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},{"id":"pmh:oai:archive.ugent.be:8653580","doi":null,"is_oa":false,"landing_page_url":"https://biblio.ugent.be/publication/8653580","pdf_url":null,"source":{"id":"https://openalex.org/S4306400478","display_name":"Ghent University Academic Bibliography (Ghent University)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I32597200","host_organization_name":"Ghent University","host_organization_lineage":["https://openalex.org/I32597200"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"ISSN: 1527-7755","raw_type":"info:eu-repo/semantics/conferenceObject"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3014055452","https://openalex.org/W4322632254","https://openalex.org/W3031596442","https://openalex.org/W4379285524","https://openalex.org/W2891248398","https://openalex.org/W3171598492","https://openalex.org/W4408997497","https://openalex.org/W4416470756","https://openalex.org/W2955945893","https://openalex.org/W2796515238"],"abstract_inverted_index":{"TPS725":[0],"Background:":[1],"T-VEC":[2,45,59,87,112,224,305],"is":[3,29,154,276],"a":[4,30,50,63,75,90],"genetically":[5],"modified,":[6],"oncolytic":[7],"herpes":[8],"simplex":[9],"virus":[10],"type":[11],"1":[12,210,220,245,267],"designed":[13],"to":[14,22,72,132,155,234,248,301,324],"selectively":[15],"replicate":[16],"within":[17],"tumors":[18],"and":[19,149,173,178,218,246,268],"produce":[20],"GM-CSF":[21],"enhance":[23],"systemic":[24,213],"antitumor":[25],"immune":[26],"responses.":[27],"Atezolizumab":[28],"monoclonal":[31],"antibody":[32],"checkpoint":[33],"inhibitor":[34],"(CPI)":[35],"that":[36,86],"targets":[37],"PD-L1.":[38],"The":[39,127,151,273,327],"safety":[40,107,287],"of":[41,44,58,108,111,159,191,232,237,251,304],"intrahepatic":[42,109],"administration":[43],"has":[46],"been":[47],"demonstrated":[48,68],"in":[49,60,65,96,113,118,135,145,171,332],"prior":[51,211],"clinical":[52],"trial":[53,57,337],"(NCT02509507).":[54],"A":[55],"previous":[56],"combination":[61,114],"with":[62,74,89,115,120,124,195,309],"CPI":[64,76,91],"advanced":[66],"melanoma":[67],"improved":[69],"responses":[70,170],"compared":[71],"those":[73],"alone":[77],"(Puzanov":[78],"et":[79],"al.":[80],"JCO.":[81],"2016;":[82],"34:2619-26).":[83],"We":[84],"hypothesize":[85],"combined":[88],"may":[92,320],"also":[93],"be":[94,226,263,307,321],"effective":[95],"other":[97],"tumor":[98],"types.":[99],"This":[100],"phase":[101],"1b,":[102],"multicenter":[103],"study":[104,128,328],"evaluates":[105],"the":[106,146,157,277,292],"injection":[110,231],"IV":[116,261],"atezolizumab":[117,258],"pts":[119,134,295],"TNBC":[121,192],"or":[122,193,207],"CRC":[123,194],"LMs.":[125],"Methods:":[126],"will":[129,225,262,289,306],"enroll":[130],"up":[131,233,247],"36":[133],"two":[136,279],"parallel":[137],"cohorts":[138],"(18":[139],"TNBC,":[140],"18":[141,187],"CRC)":[142],"at":[143],"sites":[144],"USA,":[147],"Europe,":[148],"Australia.":[150],"primary":[152],"objective":[153,166],"evaluate":[156],"incidence":[158],"dose-limiting":[160],"toxicities":[161],"(DLTs).":[162],"Secondary":[163],"objectives":[164],"include":[165,184],"response":[167],"rate,":[168],"lesion-level":[169],"injected":[172],"uninjected":[174],"tumors,":[175],"progression-free":[176],"survival,":[177],"overall":[179],"survival.":[180],"Key":[181],"eligibility":[182],"criteria":[183],"age":[185],"\u2265":[186,209,219],"years,":[188],"confirmed":[189],"diagnosis":[190],"LMs,":[196],"ECOG":[197],"performance":[198],"status":[199],"0/1,":[200],"adequate":[201],"organ":[202],"function,":[203],"disease":[204],"progression":[205],"during":[206],"after":[208,291],"standard-of-care":[212],"therapy":[214],"for":[215,330],"metastatic":[216],"disease,":[217],"measurable,":[221],"injectable":[222],"LM.":[223],"given":[227,264,308],"by":[228],"image-guided":[229],"intralesional":[230],"4":[235,249],"mL":[236,250],"106":[238],"plaque":[239],"forming":[240],"units":[241],"(PFU)/mL":[242],"on":[243,265],"day":[244,266],"108":[252],"PFU/mL":[253],"every":[254,269],"21":[255,270,284],"days":[256,271],"thereafter;":[257],"1,200":[259],"mg":[260],"thereafter.":[272],"DLT-evaluation":[274],"period":[275],"first":[278,293],"cycles":[280,303,313],"(1":[281],"cycle":[282,316],"=":[283],"days).":[285],"Interim":[286],"analysis":[288],"occur":[290],"4\u20136":[294],"have":[296],"become":[297],"DLT":[298],"evaluable.":[299],"Up":[300],"six":[302],"an":[310],"additional":[311],"6":[312],"allowed.":[314],"After":[315],"three,":[317],"nonhepatic":[318],"lesions":[319],"injected,":[322],"subject":[323],"protocol-defined":[325],"criteria.":[326],"opened":[329],"enrollment":[331],"January":[333],"2018.":[334],"(NCT03256344)":[335],"Clinical":[336],"information:":[338],"NCT03256344.":[339]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":2}],"updated_date":"2026-10-22T18:32:59.640997","created_date":"2019-02-21T00:00:00"}